CureMetrix vs DeepHealth

CureMetrix's homepage calls cmAngio the first and only FDA-cleared tool that quantifies and contextualizes breast arterial calcification, and DeepHealth's own BAC software was cleared in May 2026 (K254131). cmAngio's decisions run from K232367 in October 2023 through V1.6 in April 2025, reported to add GE platforms after Hologic, to V2.0 (K260980) in July 2026. The AUC of 0.98 to 0.992 and the 400-plus US sites are CureMetrix's own figures.

DeepHealth, a RadNet subsidiary, sells mammography detection (Saige-Dx), density (Saige-Density), triage (Saige-Q) and the iCAD ProFound line. Its reader study, 18 readers on 240 cases with AUC 0.93 against 0.87, was written by DeepHealth employees on a retrospective, enriched set.

DeepHealth suits a screening practice that wants cancer detection and BAC from one vendor, and CureMetrix is out for that buyer. Its products page, which may be dated, lists cmAssist as cleared only in Brazil and in development in the US, and openFDA shows no cmAssist 510(k). cmAngio is the draw for a breast imaging center that wants arterial calcification on its Hologic or GE fleet.